Sign in
Taking people in United StatesNo phase

Testing a New Radiation Technique for Cancer Spread to Soft Tissue

Compares lattice radiation with standard body radiation for breast or lung cancer in soft tissue.

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 7 sites
Trial code
Registry title
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status
Recruiting
People taking part
26 people, planned
Started
24 Jul 2023
Expected to end
24 Jul 2027
Type of study
Interventional
Treatments tested
  • Palliative radiotherapy
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors that have spread outside the head and who need radiation to relieve symptoms. It compares lattice radiation therapy with standard stereotactic body radiation therapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced or spread (metastatic) solid tumor confirmed by biopsy: breast (ductal or lobular), non-small cell lung, gastrointestinal (including pancreatic), bladder, kidney, melanoma or soft tissue sarcoma. At least one tumor site outside the head must measure at least 5 cm (2 in) in one direction and need palliative radiation.
Earlier treatment
No earlier radiation to the tumor sites planned for treatment. No steroid tablets or injections above normal body doses; these must be stopped during the study. Other cancer drug treatment must be held for 3 days before and 3 days after the radiation.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Earlier radiation to the same tumor sites
  • Uncontrolled infection (including HIV), uncontrolled diabetes or connective tissue disease that the doctor considers too risky
  • A second cancer that is currently active and has spread
  • Taking steroids above normal body doses

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines
  • Age ≥ 18 years
  • ECOG Performance Status of 0 or 1

Who cannot take part

  • Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed)
  • Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities
  • Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
  • Patients with a "currently active" metastatic second malignancy
  • Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study
  • Patients who are pregnant or breastfeeding
  • Unwilling or unable to participate in all required study evaluations and procedures
  • Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations)

Where in United States

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Atif Khan, MDTaking people
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesContact: Atif Khan, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

The group in the trial

  • Participants with metastatic solid tumorsTreatment being tested

    Participants will have metastatic solid tumors and at least two sites of measurable extra-cranial disease

    Treatment: Palliative radiotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases
Plain-language title
Testing a New Radiation Technique for Cancer Spread to Soft TissueGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 September 2026